Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.61 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | ATIC | P31939 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | P4HB | P07237 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TCF4 | P15884 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7571564 | 0.84 | AR (0.60) | SLC22A12FFAR4CYP19A1MAPTSMN1; SMN2 | |
| SCHEMBL7589397 | 0.81 | FFAR4 (0.52) | GPR119SLC22A12FFAR4MAPT | |
| SCHEMBL14458175 | 0.81 | ALOX15 (0.64) | GPR119SLC22A12FFAR4PGRCYP19A1 | |
| SCHEMBL26536748 | 0.81 | HSD17B2 (0.62) | GPR119SLC22A12FFAR4CYP19A1MAPT | |
| SCHEMBL31681329 | 0.81 | FFAR4 (0.65) | GPR119SLC22A12FFAR4CYP19A1MAPT | |
| SCHEMBL11028156 | 0.80 | PGR (0.64) | GPR119SLC22A12PGRATICCYP19A1 | |
| SCHEMBL7572608 | 0.80 | KMT2A (0.61) | FFAR4PGRMAPTSMN1; SMN2HDAC1 | |
| SCHEMBL27871885 | 0.79 | HTR6 (0.68) | SLC22A12PGRATICCYP19A1P4HB | |
| SCHEMBL4650279 | 0.78 | UQCRB (0.65) | SLC22A12FFAR4ATICMAPTSMN1; SMN2 | |
| SCHEMBL28561814 | 0.78 | FFAR4 (0.61) | GPR119FFAR4CYP19A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-11-06 | — | — | US | claimed |
| EP-1966131-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis Pharma AG (CH) | 2008-09-10 | — | — | EP | claimed |
| WO-2007071443-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | claimed |
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-11-06 | — | — | US | disclosed |
| EP-1966131-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis Pharma AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| EP-1966132-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071443-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007070760-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | GPR119 63/4885SLC22A12 2675/4885FFAR4 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.